Fresh analysis suggests that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop conventional lifestyle programs.
Findings released in a prominent health publication shows that while overweight individuals often shed a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Individuals using such medications must be cognizant of the risk of rapid rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.
That rate of regain suggests a return to starting weight in about one and a half years.
Weighing Treatments
The research, which reviewed dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Scientists emphasize that people who lose weight through diet and exercise usually experience a less rapid creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts believe the way of the drugs explains the accelerated regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this medication means appetite is unsuppressed, making binge eating far more likely."
An Ongoing Issue?
The NHS recommend the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, due to the significant potential of relapse, the treatment might need to be life-long.
This view is echoed by drug manufacturers, who state that the findings "highlight the long-term nature of excess weight," akin to managing diseases like high blood pressure.
User Accounts
Users who have discontinued the jabs describe a powerful resurgence of cravings.
"I experienced a switch activating and you're instantly extremely hungry," described a patient.
This difficulty is worsened if individuals have not established permanent lifestyle or habit modifications during therapy.
Growing Interest
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Use is more common among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and long-term success hinges on integrated behavioural support.
